It revealed that suppressing inflammasomes by knocking down Tmem176b in mice or utilizing TMEM176B inhibitors can improve the anti-tumor effect of CD8+ T and the efficacy of anti-CTLA-4 and anti-PD1 therapy (Segovia et al., 2019). The gene discussed is CD8A; the disease is neoplasm.